Pharmaceutical - Cardio-vascular, Financial


Current filters:


Popular Filters

Servier to appeal EC fine over perindopril

Servier to appeal EC fine over perindopril


French privately-held drugmaker Servier has said it will appeal before the European Union Court of Justice…


Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst

Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst


After facing more than 2,000 law suits in the USA, claiming Pradaxa (dabigatran) caused severe or fatal…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceutical

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation


German family-owned pharma major Boehringer Ingelheim says it has reached a comprehensive settlement…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceuticalPradaxaUSA

Ligand licenses five programs to Viking Therapeutics


US drugmaker Ligand Pharmaceuticals has out-licensed rights to five programs to Viking Therapeutics,…

Cardio-vascularDiabetesFinancialLicensingLigand PharmaceuticalsMetabolicsPharmaceuticalViking Therapeutics

Servier Canada collaborates in two research projects

Servier Canada collaborates in two research projects


Two major projects in clinical research conducted by Canada’s Montreal Heart Institute (MHI) and the…

CanadaCardio-vascularFinancialNorth AmericaPharmaceuticalResearchServier

Catalyst-rich period ahead for key trial results from BioLineRx


Israeli drug developer BioLineRx is entering a catalyst-rich phase over the next 12 months, which will…


Amarin cuts 50% of staff after negative FDA decision


Amarin has announced plans to cut 50% of its staff worldwide after the recent US Food and Drug Administration…

AmarinCardio-vascularFinancialManagementNorth AmericaPharmaceuticalVascepa

Sanofi strengthens its presence in Algeria with €70 million investment

Sanofi strengthens its presence in Algeria with €70 million investment


French drug major Sanofi revealed today that construction has begun on its new Sidi Abdellah industrial…

Cardio-vascularDiabetesFinancialPharmaceuticalProductionRest of the WorldSanofi

Statin drugs save health care systems money as well as saving lives, UK study shows


Statins not only help save lives but are great value for money too, even in lower risk patients, according…


Trevena and Forest Labs collaborate on TRV027 for acute heart failure


US GPCR ligand drug developer Trevena and Forest Laboratories (NYSE: FRX) have entered into a collaborative…

Cardio-vascularFinancialForest LaboratoriesLicensingPharmaceuticalTrevenaTRV027

Merck & Co opens new $120 million manufacturing plant in China


US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Proposal to list AstraZeneca's Brilinta in New Zealand


New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to fund the…


Financing for Life Sciences Entrepreneurs antiplatelet candidate NmC; and Ambit's AML drug


Life Science Entrepreneurs, a Spanish company dedicated to the early-stage development of high-risk/very…

Ambit BiosciencesCardio-vascularFinancialLife Sciences EntrepreneursNmCOncologyPharmaceuticalquizartinibResearch

Isis earns $25 million milestone from Genzyme as US FDA accepts Kynamro NDA


The US Food and Drug Administration has accepted for filing the New Drug Application for Kynamro (mipomersen…

BiotechnologyCardio-vascularFinancialGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRegulationSanofi

AstraZeneca CEO to go early, as 1st-qtr sales and profits plunge; makes deal with TMC for cardiovasculars


Anglo-Swedish drug major AstraZeneca (LSE: AZN) stunned the markets this morning, announcing that its…

AstraZenecaCardio-vascularFinancialLicensingManagementPharmaceuticalThe Medicines Company

Merck & Co drops development of oral vernakalant


ug giant Merck & Co (NYSE: MRK) has discontinued further development of the oral formulation of vernakalant,…

BrinavessCardio-vascularCardiome PharmaFinancialMerck & CoPharmaceuticalResearchvernakalant

Lipitor and strategic collapse at Pfizer, a consultants view


Now global pharma behemoth Pfizer (NYSE: PFE) spent $114 billion in 2000 for a hostile takeover of Warner-Lambert,…

Cardio-vascularFinancialLipitorMarkets & MarketingPfizerPharmaceutical

Bayer boasts four potential pipeline blockbusters


German drugs and crop and material sciences group Bayer (BAT: DE) said yesterday that it plans to continue…

AlpharadinBayerCardio-vascularEyleaFinancialMarkets & MarketingOncologyOphthalmicsPharmaceuticalregorafenibResearchXarelto

Merck & Co highlights pipeline progress; plans eight US filings in 2012-


US pharma giant Merck & Co (NYSE:MRK) hosted an upbeat R&D and Business Briefing yesterday, where it…

Anti-Arthritics/RheumaticsBridonCardio-vascularFinancialMerck & CoNeurologicalodanacatibOncologyPharmaceuticalRegulationResearchsuvorexantTredaptive

Back to top